Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine.

Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M

Cephalalgia : an international journal of headache1 Mar 2008Cited by 206 (Europe PMC)

PMID18254893DOI10.1111/j.1468-2982.2007.01497.xPepBankPUB-18254893

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialSafety outcome
In people with migraine without aura, intravenous VIP infusion did not trigger a migraine attack in any participant.
In plain wordsIn people with migraine, an infusion of VIP did not trigger a migraine attack in any of them.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeMigraine attacks after VIP infusion
Study
n = 12
Comparator
Placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
8 pmol kg(-1) min(-1) · intravenous infusionAs given in this study (human).
Source sentences
Summary
None of the subjects reported a migraine attack after VIP infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with migraine without aura were allocated to receive 8 pmol kg(-1) min(-1) VIP or placebo in a randomized, double-blind crossover study.
Report a problemFND-1825489301
02HumanRandomized controlled trialSafety outcome
In people with migraine without aura, VIP infusion caused a mild immediate headache that was greater than with placebo.
In plain wordsIn people with migraine, VIP caused a mild headache right after the infusion, more than placebo did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseImmediate headache after VIP infusion
Study
n = 12
Comparator
Placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
8 pmol kg(-1) min(-1) · intravenous infusionAs given in this study (human).
Measurements
Maximum headache score
2 VRS
VIP
Source sentences
Summary
VIP induced a mild immediate headache (maximum 2 on VRS) compared with placebo (P = 0.005).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with migraine without aura were allocated to receive 8 pmol kg(-1) min(-1) VIP or placebo in a randomized, double-blind crossover study.
Report a problemFND-1825489302
03HumanRandomized controlled trialSafety outcome
In people with migraine without aura, delayed headache 3 to 11 hours after infusion did not differ significantly between VIP and placebo.
In plain wordsIn people with migraine, headaches a few hours after the infusion were not significantly more frequent with VIP than with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeDelayed headache after VIP infusion
Study
n = 12
Comparator
Placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
8 pmol kg(-1) min(-1) · intravenous infusionAs given in this study (human).
Measurements
Patients with delayed headache
3 patients
VIP
Patients with delayed headache
2 patients
placebo
Source sentences
Summary
Three patients reported delayed headache (3-11 h after infusion) after VIP and two after placebo (P = 0.89).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with migraine without aura were allocated to receive 8 pmol kg(-1) min(-1) VIP or placebo in a randomized, double-blind crossover study.
Report a problemFND-1825489303
04HumanRandomized controlled trialMechanism
In people with migraine without aura, VIP infusion decreased mean blood flow velocity in the middle cerebral artery.
In plain wordsIn people with migraine, VIP infusion slowed blood flow in a main brain artery.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseMiddle cerebral artery blood flow velocity
Study
n = 12
Outcome group
Cerebral blood flow · Cardiovascular
Studied dose
8 pmol kg(-1) min(-1) · intravenous infusionAs given in this study (human).
Measurements
Change in V(mean MCA)
−16.3%
VIP
Source sentences
Summary
V(mean MCA) decreased (16.3 +/- 5.9%)
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with migraine without aura were allocated to receive 8 pmol kg(-1) min(-1) VIP or placebo in a randomized, double-blind crossover study.
Report a problemFND-1825489304
05HumanRandomized controlled trialMechanism
In people with migraine without aura, VIP infusion significantly increased the diameter of the superficial temporal artery.
In plain wordsIn people with migraine, VIP infusion widened an artery in the temple.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseSuperficial temporal artery diameter
Study
n = 12
Outcome group
Cerebral blood flow · Cardiovascular
Studied dose
8 pmol kg(-1) min(-1) · intravenous infusionAs given in this study (human).
Measurements
Change in STA diameter
45.9%
VIP
Source sentences
Summary
diameter of STA increased significantly after VIP (45.9 +/- 13.9%).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with migraine without aura were allocated to receive 8 pmol kg(-1) min(-1) VIP or placebo in a randomized, double-blind crossover study.
Report a problemFND-1825489305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.